Literature DB >> 9355080

Relationship between left ventricular hypertrophy and plasma renin activity in chronic hemodialysis patients.

D V Vlahakos1, G Hahalis, P Vassilakos, K P Marathias, S Geroulanos.   

Abstract

Left ventricular hypertrophy (LVH) is very common in uremic patients. It was shown previously that hemodialysis patients are chronically exposed to the extremes of plasma renin activity due to differences in the original renal disease. Because nonhemodynamic factors seem to play a fundamental role in the development of LVH, the present study was undertaken to investigate the relationship between the predialysis renin level and the echocardiographically determined cardiac structure in stable hemodialysis patients, matched for other parameters known to participate in the development of LVH, such as age; gender; body mass index; interdialytic weight gain; heart rate; systolic, diastolic, and mean arterial BP; hematologic and biochemical profile; vascular access; adequacy of dialysis; nutritional status; and period of follow-up. Thirty-three such patients were stratified in three groups according to predialysis renin levels: group A (n = 11), with renin levels < or = 1 ng.ml-1.h-1; group B (n = 9), with renin levels between 1 and 4 ng.ml-1.h-1; and group C (n = 13), with renin levels > or = 4 ng.ml-1.h-1. LVH with disproportionate septal thickening was directly related to the degree of renin-angiotensin system activation, and values for interventricular septum thickness, posterior wall thickness, interventricular septum thickness/posterior wall thickness ratio, left ventricular mass, and left ventricular mass index were all significantly correlated with predialysis renin levels. Because angiotensin II promotes growth in both fibroblasts and cardiac myocytes, these relationships suggest that elevated renin levels may be causally associated with the development of LVH in chronic hemodialysis patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9355080     DOI: 10.1681/ASN.V8111764

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  7 in total

Review 1.  Uremic Toxins - Novel Arrhythmogenic Factor in Chronic Kidney Disease - Related Atrial Fibrillation.

Authors:  Shih-Yu Huang; Yi-Ann Chen; Shih-Ann Chen; Yi-Jen Chen; Yung-Kuo Lin
Journal:  Acta Cardiol Sin       Date:  2016-05       Impact factor: 2.672

2.  Reverse Remodeling and Prognosis Following Kidney Transplantation in Contemporary Patients With Cardiac Dysfunction.

Authors:  Nael Hawwa; Kevin Shrestha; Muhammad Hammadah; Poh Shuan Daniel Yeo; Richard Fatica; W H Wilson Tang
Journal:  J Am Coll Cardiol       Date:  2015-10-20       Impact factor: 24.094

3.  Speckle tracking echocardiography detects uremic cardiomyopathy early and predicts cardiovascular mortality in ESRD.

Authors:  Rafael Kramann; Johanna Erpenbeck; Rebekka K Schneider; Anna B Röhl; Marc Hein; Vincent M Brandenburg; Merel van Diepen; Friedo Dekker; Nicolaus Marx; Jürgen Floege; Michael Becker; Georg Schlieper
Journal:  J Am Soc Nephrol       Date:  2014-04-03       Impact factor: 10.121

Review 4.  Cardiovascular effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in hemodialysis: a meta-analysis.

Authors:  Davina J Tai; Thomas W Lim; Matthew T James; Braden J Manns; Marcello Tonelli; Brenda R Hemmelgarn
Journal:  Clin J Am Soc Nephrol       Date:  2010-02-04       Impact factor: 8.237

5.  Comparison of Left Ventricular Hypertrophy, Fibrosis and Dysfunction According to Various Disease Mechanisms such as Hypertension, Diabetes Mellitus and Chronic Renal Failure.

Authors:  Yoon-Seok Koh; Hae-Ok Jung; Mahn-Won Park; Joo-Yeoul Baek; Sung-Gyu Yoon; Pum-Joon Kim; Sang-Hyun Ihm; Kiyuk Chang; Yong-Seog Oh; Ho-Joong Youn; Sang Hong Baek; Wook-Sung Chung; Ki-Bae Seung; Jae-Hyung Kim
Journal:  J Cardiovasc Ultrasound       Date:  2009-12-31

6.  Chronic kidney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a non-dialysable uremic toxin, indoxyl sulfate.

Authors:  Suree Lekawanvijit; Andrew R Kompa; Minako Manabe; Bing H Wang; Robyn G Langham; Fuyuhiko Nishijima; Darren J Kelly; Henry Krum
Journal:  PLoS One       Date:  2012-07-19       Impact factor: 3.240

7.  ACE inhibition attenuates uremia-induced aortic valve thickening in a novel mouse model.

Authors:  Mikko A Simolin; Tanja X Pedersen; Susanne Bro; Mikko I Mäyränpää; Satu Helske; Lars B Nielsen; Petri T Kovanen
Journal:  BMC Cardiovasc Disord       Date:  2009-03-03       Impact factor: 2.298

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.